Skip to content

Mescaline research published in 2024

24 studies whose primary subject is mescaline were published in 2024, down from 35 in 2023. Newest first. Back to the mescaline overview

Studies

Exploring the regulatory framework of psychedelics in the US & Europe.

Asian Journal of Psychiatry December 1, 2024 Hitesh Kumar Behera, Ramesh Joga, Sravani Yerram et al.

Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic stress disorder (PTSD), and anxiety. Psychedelic treatment differs from conventional psychiatric approaches in mode of action, legal status, and treatment approach. This work delves into the therapeutic potential, mechanisms, and regulatory...

Mescaline-induced behavioral alterations are mediated by 5-HT2A and 5-HT2C receptors in rats.

Pharmacology, Biochemistry, and Behavior December 1, 2024 Lucie Olejníková-Ladislavová, Michaela Fujáková-Lipski, Klára Šíchová et al. 5 citations

Mescaline is a classical psychedelic compound with a phenylethylamine structure that primarily acts on serotonin 5-HT2A/C receptors, but also binds to 5-HT1A and 5-HT2B receptors. Despite being the first psychedelic ever isolated and synthesized, the precise role of different serotonin receptor subtypes in its behavioral pharmacology is not fully understood. In this study, we aimed to...

DOI: 10.1016/j.pbb.2024.173903 (opens in new tab) Full text (opens in new tab) Mescaline Psychedelics hallucinogens Locomotor activity Sensorimotor gating +6

Safety pharmacology of acute mescaline administration in healthy participants.

British Journal of Clinical Pharmacology November 25, 2024 Aaron Klaiber, Mélusine Humbert‐droz, Laura Ley et al. 6 citations

Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. The present pooled analysis included two double-blind, randomized, placebo-controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral-dose administrations (n = 16/dose) of mescaline at doses of 100-800 mg were...

Pattern of psychedelic substance use: a comparison between populations in Spain and South America using the Psychedelic Use Scale (PUS)

Current Psychology November 21, 2024 Jaime Rojas-Hernández, Lucas F Borkel, Domingo Jesús Quintana Hernández et al. 6 citations

Abstract Psychedelic use has increased in the last decade. However, it is unclear whether the cultural background of the consumers exerts any influence. The aim of the present study was to determine the pattern of psychedelic use in Spain and Spanish-speaking populations in South America and compare these consumption patterns to understand the use of these substances in two culturally distinct...

Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.

Pharmaceuticals November 5, 2024 Tamara Valdez, Valbhi Patel, Nattaphone Senesombath et al. 4 citations

Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (SUDs). Despite early mid-20th century anecdotal reports and pilot studies demonstrating the possibility of these substances in efficaciously treating conditions such as alcohol and opioid use disorders, legal restrictions and social stigma have...

Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects.

Translational Psychiatry September 30, 2024 Aaron Klaiber, Yasmin Schmid, Anna M Becker et al. 27 citations

Classic psychedelics have regained interest in research and therapy. Despite the long tradition of the human use of mescaline, modern data on its dose-dependent acute effects and pharmacokinetics are lacking. Additionally, its mechanism of action has not been investigated in humans. We used a randomized, double-blind, placebo-controlled, crossover design in 16 healthy subjects (8 women) who...

Psychedelics: From Cave Art to 21st-Century Medicine for Addiction

European Addiction Research September 25, 2024 Ioanna A. Vamvakopoulou, David Nutt 13 citations

Background: Psychedelic substance use in ritualistic and ceremonial settings dates back as early as 8,500 BCE. Only in recent years, from the mid-20th century, we have seen the re-emergence of psychedelics in a therapeutic setting and more specifically for the treatment of addiction. This article aims to review research over the past 40 years using classic (psilocybin, lysergic acid...

New frontiers in the biosynthesis of psychoactive specialized metabolites

Current Opinion in Plant Biology September 16, 2024 Ginny Li, Peter J. Facchini 6 citations

The recent relaxation of psychedelic drug regulations has prompted extensive clinical investigation into their potential use to treat diverse mental health conditions including anxiety, depression, post-traumatic stress, and substance-abuse disorders. Most clinical trials have relied on a small number of known molecules found in nature, such as psilocybin, or long-known synthetic analogs of...

The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies

Progress in Neuro-Psychopharmacology and Biological Psychiatry September 7, 2024 Zhen Xuen Brandon Low, Wei Shen Ng, Bey Hing Goh et al. 19 citations

Emerging evidence suggests that classical psychedelics possess immunomodulatory and anti-inflammatory properties; however, these effects are yet to be well-established. This systematic review aims to provide a timely and comprehensive overview of the immunomodulatory effects of classical psychedelics in preclinical studies. A systematic search was conducted on six databases, including CINAHL,...

Jung, the Rebirth Motif and Psychedelics I: Documenting Jung's Contact with the British Pioneers.

Journal of Analytical Psychology September 1, 2024 Ginny Hill 1 citation

C. G. Jung wrote very little about psychedelic drugs and he took a sceptical view of them. However, he was sufficiently impressed by Aldous Huxley's 1954 account of taking mescaline, The Doors of Perception, to invite Huxley to visit him in Switzerland. Huxley declined Jung's invitation but Huxley's collaborator Humphry Osmond met Jung instead. This paper documents Jung's contact with the...

Behavioral pharmacology of mescaline - the role of serotonin 5-HT2A, 5-HT2B, 5-HT2C and 5-HT1A receptors

bioRxiv Preprint Server August 28, 2024 Lucie Olejníková-Ladislavová, Michaela Fujáková-Lipski, Klára Šíchová et al. preprint

Rationale Mescaline is a classical psychedelic compound with a phenylethylamine structure that primarily acts on serotonin 5-HT2A/C receptors, but also binds to 5-HT1A and 5-HT2B receptors. Despite being the first psychedelic ever isolated and synthesized, the precise role of different serotonin receptor subtypes in its behavioral pharmacology is not fully understood.

Hitting the Reset Button: Ceremonial Use of Peyote and Experiences of Personal Change

Journal of Drug Issues August 22, 2024 Heith Copes, Andrew Hochstetler, Jared Ragland et al. 3 citations

Our aim is to understand how those who use peyote in a naturalistic setting discuss it changed their lives and to what they attribute this change. To do this, we draw on data from a photo-ethnography of people who attended peyote ceremonies in rural Northcentral Alabama. Broadly, we found that participants discussed four core areas of change: reduced drug and alcohol misuse, new perspectives on...

Plant drugs: Transcending the mescaline biosynthesis.

Current Biology August 19, 2024 Vincent Courdavault, Nicolas Papon 1 citation

Our knowledge of the biosynthesis of medicinal compounds from plants remains limited. A new study has deciphered the complete metabolic pathway leading to the biosynthesis of the psychedelic mescaline in the cactus peyote, suggesting the development of biotechnological strategies for a sustainable supply of this important plant drug.

DOI: 10.1016/j.cub.2024.06.061 (opens in new tab) Full text (opens in new tab) Psychedelics Plant biochemistry Natural compounds Conservation biology +1

How psychedelics legalization debates could differ from cannabis

Addiction August 13, 2024 Beau Kilmer 3 citations

An increasing number of US states and localities are implementing or considering alternatives to prohibiting the supply and possession of some psychedelics for non-clinical use. Debates about these policy changes will probably differ from what we saw with cannabis. Andrews et al. correctly note that: 'The current push to broaden the production, sale, and use of psychedelics bears many parallels...

Psychedelic trip sitting, dosages and intensities: Supplementing clinical studies with anecdotal reports

Journal of Psychedelic Studies July 17, 2024 Liam Engel, Sascha Thal, Stephen Bright et al. 4 citations

Abstract Background and aims Online communities provide insights into psychedelic consumption, assisting in identification of trends, informing both harm reduction provisions and clinical research. This study extracts forum data on psychedelic substances, dosages, and administration routes, categorising and analysing self-reported consumption to inform care services and guide clinical work with...

The biosynthetic pathway of the hallucinogen mescaline and its heterologous reconstruction

Molecular Plant June 3, 2024 Paula Berman, Luis Alejandro de Haro, Ana-Rita Cavaco et al. 15 citations

Mescaline, among the earliest identified natural hallucinogens, holds great potential in psychotherapy treatment. Nonetheless, despite the existence of a postulated biosynthetic pathway for more than half a century, the specific enzymes involved in this process are yet to be identified. In this study, we investigated the cactus Lophophora williamsii (Peyote), the largest known natural producer...

DOI: 10.1016/j.molp.2024.05.012 (opens in new tab) Mescaline Heterologous Computational biology Hallucinogen +1

Psilocybin, peyote, mescaline, and lysergic acid diethylamide (LSD) use in a nationally representative population by cancer history.

Journal of Clinical Oncology June 1, 2024 Amrit Baral, Yue Pan, Alberto J. Caban Martinez et al.

e22518 Background: Classic psychedelics (Peyote, Psilocybin, Mescaline, and LSD) are re-emerging in the oncology toolbox. Peyote is the oldest known psychedelic, yet underexplored in clinical research. Preclinical studies suggest its extract stimulates lymphocyte proliferation, kills tumor cells, and may regulate sleep. This study aims to estimate the prevalence of classic psychedelic use among...

Therapeutics Uses of Psychedelics in patients with psychiatric disorders A Systematic Review

Journal For International Medical Graduates April 18, 2024 Sarosh Nawaz, Abdulaziz Mohammed Althwanay, B Esraa M. Aledani Mb Ch et al.

The impact of psychedelic treatment on patients suffering from psychiatric diseases like depression, anxiety, post-traumatic psychiatric disorder (PTSD), and existential distress related to cancer has become very intriguing to psychiatrists in the modern era. Serotonergic psychedelics include Lysergic acid diethylamide (LSD), psilocybin, mescaline, ayahuasca, and methylene-deoxy methamphetamine...

The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.

Clinical Toxicology April 1, 2024 Rachael Wilkes, Darren M Roberts, Paul Liknaitzky et al. 8 citations

The global use of certain classical psychedelics has increased in recent years, but little is known about their spectrum of toxicity within Australia. We aim to describe calls to New South Wales Poisons Information Centre relating to exposures to classical psychedelics including lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, ayahuasca, mescaline and ibogaine. This is a...

Peyote Shrines, Remembrance, and Ritual Surrogacy in South Texas

Journal for the Study of Religion, Nature and Culture March 13, 2024 Servando Z. Hinojosa

Peyote grows in South Texas where licensed dealers acquire it and sell it to Native American Church members. These dealers also create and maintain special shrines on their property for the visiting buyers. The shrines not only mark a portal of entry into the region but also comprise the only opportunity many Native Americans will have to see peyote growing in the ground. Prompting prayers and...

DOI: 10.1558/jsrnc.22667 (opens in new tab) Ethnology Archaeology Ancient history Anthropology